Carcinogenesis Advance Access originally published online on November 25, 2004
Carcinogenesis 2005 26(3):565-570; doi:10.1093/carcin/bgh340
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.26 no.3 © Oxford University Press 2004; all rights reserved.
ARTICLE |
A COX-2 inhibitor prevents the esophageal inflammation–metaplasia–adenocarcinoma sequence in rats
Gastroenterologic Surgery, Department of Oncology, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan
* To whom correspondence should be addressed Email: kmiwa{at}surg2.m.kanazawa-u.ac.jp
Barrett's esophagus (BE) and esophageal adenocarcinoma (ADC) is associated with reflux of duodenal contents. Cyclooxygenase (COX)-2 is over-expressed in BE and ADC, and supposedly contributes to esophageal carcinogenesis. The aim of this study is to investigate what effect a COX-2 inhibitor has on esophageal adenocarcinogenesis in rats. A series of 90 rats underwent a duodenoesophageal reflux procedure and were divided into 2 groups. One group was given commercial chow (control group), and the other was given experimental chow containing celecoxib (celecoxib group). The animals were sacrificed sequentially, at the 10th, 20th, 30th and, finally, 40th week after surgery, and their esophagi were examined. In the control group, esophagitis, columnar-lined epithelium (CLE) and ADC were first observed at the 10th week, 20th week and 30th week, respectively. Their incidences sequentially increased and at the 40th week reached 100, 89 and 47%, respectively. In the celecoxib group, the esophagitis was mild and the incidence of CLE was significantly lower at each week (P < 0.001), compared with the control group, and ADC was not observed throughout the experiment (P < 0.05). COX-2 expression was observed predominantly in the stroma of inflamed esophageal epithelia, and up-regulated at the 10th and 20th week (P < 0.05, respectively). PGE2 level and proliferative activity were also up-regulated in both groups, but they were lower in the celecoxib group than in the control group (P < 0.05). Apoptosis was observed to increase with celecoxib treatment (P < 0.05). Celecoxib is effective in preventing CLE and ADC by suppressing esophagitis in rats.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L.M.G. Moons, J.G. Kusters, J.H.M. van Delft, E.J. Kuipers, R. Gottschalk, H. Geldof, W.A. Bode, J. Stoof, A.H.M. van Vliet, H.B. Ketelslegers, et al. A pro-inflammatory genotype predisposes to Barrett's esophagus Carcinogenesis, May 1, 2008; 29(5): 926 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bonde, G. Sui, S. Dhara, J. Wang, A. Broor, I. F. Kim, J. E. Wiley, G. Marti, M. Duncan, E. Jaffee, et al. Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 763 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R C Fitzgerald Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, December 1, 2006; 55(12): 1810 - 1820. [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Anderson, B. T. Johnston, R.G. P. Watson, S. J. Murphy, H. R. Ferguson, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence. Cancer Res., May 1, 2006; 66(9): 4975 - 4982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Souza and S. J. Spechler Concepts in the Prevention of Adenocarcinoma of the Distal Esophagus and Proximal Stomach CA Cancer J Clin, November 1, 2005; 55(6): 334 - 351. [Abstract] [Full Text] [PDF]
|
|